Want to see SE:BIOA.B full AI Analyst Report?
Top Page
BioArctic AB Class B
(BIOA.B)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr316.00
▼(-8.41% Downside)
Action:Downgraded
Date:08/28/26
The score is primarily supported by solid financial quality (strong current profitability and low leverage) and a modestly positive technical setup (price above key moving averages with neutral momentum). These positives are meaningfully tempered by valuation risk driven by the very high P/E and by variability in revenue and cash-flow trends.
Positive Factors
Low leverage
Very low leverage limits financial risk and reduces the burden of interest or refinancing obligations. A strong equity base gives BioArctic greater flexibility to continue research, support partnered programs, and absorb earnings fluctuations without relying heavily on additional debt.
Negative Factors
Revenue contraction
A sharp decline in the revenue run-rate weakens near-term visibility into the company’s recurring earning base. Because partnering revenue can depend on milestones and collaboration timing, sustained contraction would make it harder to plan investment and demonstrate consistent commercial progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage limits financial risk and reduces the burden of interest or refinancing obligations. A strong equity base gives BioArctic greater flexibility to continue research, support partnered programs, and absorb earnings fluctuations without relying heavily on additional debt.
Read all positive factors
BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr28.42B
Dividend Yield0.67%
Average Volume (3M)107.36K
Price to Earnings (P/E)269.1
Beta (1Y)0.40
Revenue Growth-46.09%
EPS Growth-90.13%
CountrySE
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.19
Shares Outstanding74,344,690
10 Day Avg. Volume96,955
30 Day Avg. Volume107,355
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.72
Revenue Forecast (FY)kr1.33B
BioArctic AB Class B Business Overview & Revenue Model
Company Description
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The co...
How the Company Makes Money
BioArctic primarily makes money through partnering and licensing its drug programs to larger pharmaceutical companies that fund significant parts of clinical development, regulatory work, and commercialization. Key revenue streams typically includ...
BioArctic AB Class B Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00B | 2.00B | 257.35M | 616.00M | 228.29M | 23.15M |
| Gross Profit | 933.97M | 1.94B | 230.37M | 526.37M | 153.97M | -31.92M |
| EBITDA | 227.69M | 1.38B | -176.95M | 295.29M | 3.58M | -126.63M |
| Net Income | 105.52M | 1.02B | -177.08M | 229.25M | -11.18M | -119.79M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.58B | 1.11B | 1.19B | 858.31M | 897.73M |
| Cash, Cash Equivalents and Short-Term Investments | 1.99B | 2.19B | 778.92M | 1.11B | 805.39M | 848.40M |
| Total Debt | 90.61M | 44.07M | 54.23M | 4.98M | 10.04M | 15.88M |
| Total Liabilities | 802.78M | 608.14M | 216.74M | 139.50M | 72.06M | 109.05M |
| Stockholders Equity | 2.02B | 1.97B | 894.94M | 1.05B | 786.24M | 788.68M |
Cash Flow | ||||||
| Free Cash Flow | 106.14M | 1.42B | -342.97M | 302.25M | -44.38M | -144.84M |
| Operating Cash Flow | 243.98M | 1.43B | -316.33M | 309.69M | -31.64M | -140.46M |
| Investing Cash Flow | 42.30M | -894.65M | 205.63M | -507.49M | -12.76M | -4.41M |
| Financing Cash Flow | -153.68M | 26.91M | 5.69M | 14.06M | -2.81M | -7.39M |
BioArctic AB Class B Technical Analysis
Positive
345.00
Price Trends
314.62
Positive
314.30
Positive
316.17
Positive
Market Momentum
-0.71
Negative
61.87
Neutral
91.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOA.B, the sentiment is Positive. The current price of 345 is above the 20-day moving average (MA) of 299.54, above the 50-day MA of 314.62, and above the 200-day MA of 316.17, indicating a bullish trend. The MACD of -0.71 indicates Negative momentum. The RSI at 61.87 is Neutral, neither overbought nor oversold. The STOCH value of 91.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOA.B.
BioArctic AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr28.42B | 269.08 | 5.18% | 0.67% | -46.09% | -90.13% | |
68 Neutral | kr1.59B | 8.58 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr304.86M | -3.15 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr899.09M | 43.67 | 65.99% | ― | ― | ― | |
48 Neutral | kr1.36B | -2.74 | -99.58% | ― | -87.22% | -70.29% | |
44 Neutral | kr117.42M | -1.76 | -17.52% | ― | -100.00% | 20.94% |
* Healthcare Sector Average
SE:BIOA.B
BioArctic AB Class B
319.40
31.11
10.79%
SE:BINV
BioInvent International AB
5.71
-27.59
-82.85%
SE:ALZ
Alzinova AB
0.38
-1.08
-74.23%
SE:ALZCUR
AlzeCure Pharma AB
6.50
4.57
237.49%
SE:SANION
Saniona AB
11.45
-3.35
-22.64%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
2.12
-0.32
-12.97%
BioArctic AB Class B Corporate Events
BioArctic’s Leqembi Begins First Real-World Use in Sweden After EU Approval
Sep 22, 2026
BioArctic AB said that Leqembi, its Alzheimer’s drug developed with Eisai, has become available at a private clinic in Sweden, where the first patient outside a clinical study has now started treatment since the therapy’s EU approval i...
Japan Approves At-Home Leqembi Pen for Early Alzheimer’s Treatment
Sep 16, 2026
Eisai, BioArctic’s partner in Alzheimer’s therapeutics, has secured Japanese approval for Leqembi Pen, a subcutaneous autoinjector formulation of lecanemab for early Alzheimer’s disease. The new route complements the existing int...
BioArctic Partner Eisai Wins China Approval for At-Home Leqembi Alzheimer’s Autoinjector
Sep 3, 2026
BioArctic’s partner Eisai has secured approval from China’s National Medical Products Administration for the Leqembi subcutaneous autoinjector formulation as an initiation treatment for patients with mild cognitive impairment or mild d...
BioArctic’s Leqembi Wins Key Canadian Reimbursement Backing
Sep 1, 2026
BioArctic’s partner Eisai has secured a final positive recommendation from Canada’s Drug Agency supporting public reimbursement of Leqembi for eligible patients with mild cognitive impairment or mild dementia due to early AlzheimerR...
BioArctic Updates Share and Vote Structure After Stock Option Exercise
Aug 31, 2026
BioArctic AB has slightly expanded its share capital following the issuance of 20,200 Class B shares in August 2026 to fulfill obligations under its long-term stock option program adopted in 2019. The move reflects the ongoing use of equity-based ...
BioArctic Deepens Alzheimer’s Footprint With Leqembi Expansion and New Strategic Alliances
Aug 26, 2026
BioArctic reported second-quarter 2026 net revenues of SEK 247.5 million, with royalty income from Alzheimer’s drug Leqembi rising to SEK 179.4 million, but posted a small operating loss amid heavy RD spending that accounted for 73% of opera...
BioArctic and Eisai Expand At-Home Alzheimer’s Treatment With U.S. Launch of Leqembi Iqlik
Aug 24, 2026
BioArctic’s partner Eisai has launched Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab, in the U.S. for initiation therapy in early Alzheimer’s disease, offering at-home dosing for both initiation and maintenance. T...
BioArctic and Mesenkia team up on novel glioblastoma therapy
Aug 19, 2026
BioArctic and Mesenkia Therapeutics have entered a research collaboration to develop a novel antibody-based treatment approach for glioblastoma, one of the most aggressive and treatment-resistant brain cancers. The partnership combines BioArctic&#...
BioArctic schedules August 26 webcast for Q2 2026 report
Aug 19, 2026
BioArctic AB announced it will release its second quarter report for the period April to June 2026 on August 26 at 8:00 a.m. CEST. The timing underscores the company’s ongoing communication efforts with the market as it advances its neurodeg...
BioArctic’s Leqembi Royalties Surge on Strong Global Q2 Sales
Jul 29, 2026
BioArctic reported that partner Eisai’s Alzheimer’s drug Leqembi generated global sales of JPY 29.3 billion in the second quarter of 2026, translating into royalty income of SEK 179 million for the Swedish biopharma group. This represe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.